Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Public ClinicalTrials.gov record NCT04068896. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Dose-Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
Study identification
- NCT ID
- NCT04068896
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- NGM Biopharmaceuticals, Inc
- Industry
- Enrollment
- 89 participants
Conditions and interventions
Conditions
Interventions
- NGM120 100mg Biological
- NGM120 100mg Q3W Biological
- NGM120 100mg with Gemcitabine and Abraxane Biological
- NGM120 30mg Biological
- NGM120 30mg with Gemcitabine and Abraxane Biological
- Placebo Other
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 15, 2019
- Primary completion
- Sep 20, 2023
- Completion
- Jan 7, 2024
- Last update posted
- May 28, 2025
2019 – 2024
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| NGM Clinical Study Site | Tucson | Arizona | 85719 | — |
| NGM Clinical Study Site | Los Angeles | California | 90048 | — |
| NGM Clinical Study Site | Los Angeles | California | 90084 | — |
| NGM Clinical Study Site | Sacramento | California | 98517 | — |
| NGM Clinical Study Site | San Diego | California | 92123 | — |
| NGM Clinical Study Site | Santa Monica | California | 90404 | — |
| NGM Clinical Study Site | Aurora | Colorado | 80045 | — |
| NGM Clinical Study Site | Washington D.C. | District of Columbia | 20007 | — |
| NGM Clinical Study Site | Miami | Florida | 33136 | — |
| NGM Clinical Study Site | Chicago | Illinois | 60611 | — |
| NGM Clinical Study Site | Baltimore | Maryland | 21201 | — |
| NGM Clinical Study Site | Cincinnati | Ohio | 45219 | — |
| NGM Clinical Study Site | Philadelphia | Pennsylvania | 19111 | — |
| NGM Clinical Study Site | Charleston | South Carolina | 29425 | — |
| NGM Clinical Study Site | Myrtle Beach | South Carolina | 29572 | — |
| NGM Clinical Study Site | Nashville | Tennessee | 37203 | — |
| NGM Clinical Study Site | Dallas | Texas | 75390 | — |
| NGM Clinical Study Site | Houston | Texas | 77030 | — |
| NGM Clinical Study Site | Seattle | Washington | 98101 | — |
| NGM Clinical Study Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04068896, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 28, 2025 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04068896 live on ClinicalTrials.gov.